| 胰高血糖素样肽-1的心血管益处及机制 |
| |
| 引用本文： | 钟兴,刘媛媛,肖海鹏.胰高血糖素样肽-1的心血管益处及机制[J].中国新药杂志,2011(21). |
| |
| 作者姓名： | 钟兴 刘媛媛 肖海鹏 |
| |
| 作者单位： | 中山大学附属第一医院内分泌科; |
| |
| 摘 要： | 心血管疾病是2型糖尿病患者的主要死亡原因之一。新近研究发现胰高血糖素样肽-1(GLP-1)不仅通过葡萄糖依赖的方式刺激胰岛素分泌和抑制糖原的不适当分泌,延缓胃排空,增加饱食感等方式调节血糖;还能通过GLP-1R和受体以外的方式发挥心血管保护作用,包括心肌、内皮细胞和血管等。越来越多的动物和临床研究显示,GLP-1和GLP-1R激动剂都能改善内皮细胞功能、促进钠的排泄、改善缺血损伤的心肌和心功能的恢复,减少心血管风险的危险因素和标志物。文中综述有关动物和人类研究中GLP-1对心血管系统的作用以及可能机制。
|
| 关 键 词： | 胰高血糖素样肽-1 2型糖尿病 心血管疾病 利拉鲁肽 艾塞那肽 |
Cardiovascular benefits of glucagon-like peptide-1 and the mechanisms |
| |
| ZHONG Xing,LIU Yuan-yuan,XIAO Hai-peng.Cardiovascular benefits of glucagon-like peptide-1 and the mechanisms[J].Chinese Journal of New Drugs,2011(21). |
| |
| Authors: | ZHONG Xing LIU Yuan-yuan XIAO Hai-peng |
| |
| Institution: | ZHONG Xing,LIU Yuan-yuan,XIAO Hai-peng(Department of Endocrinology,First Affiliated Hospital,Sun Yat-sen University,Guangzhou 510080,China) |
| |
| Abstract: | Cardiovascular disease(CVD) is one of the leading causes of death in patients with type 2 diabetes.Recent studies have shown that glucagon-like peptide-1(GLP-1) regulates blood glucose concentrations;the mechanisms include enhancing insulin secretion,suppressing glucagon secretion,slowing gastric emptying,and enhancing satiety.GLP-1 also exerts a beneficial effect on myocardium,endothelium and vasculature mediated by the GLP-1 receptors(GLP-1R) and the GLP-1R-independent pathways.Growing lines of evidence f... |
| |
| Keywords: | glucagon-like peptide-1 type 2 diabetes cardiovascular disease liraglutide exenatide |
| 本文献已被 CNKI 等数据库收录！ |
|
